Johnson & Johnson to buy Biopsys

Article

Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum

Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum method for removing breast tissue. The merger is subject to approval by Biopsys shareholders and regulatory authorities.

The amount of Johnson & Johnson stock that will be issued for each Biopsys share will be based on a formula in which $27.55 will be divided by the average closing price per J&J share for each of the 20 trading days preceding the last full trading day prior to a meeting of Biopsys shareholders to approve the merger. Biopsys shares closed at $26.69 the day the merger was announced.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.